Humana (HUM)

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.

Jim Cramer weighed in on the deepening crisis at one of America's largest health insurers, which has lately found itself under intense scrutiny by the public, regulators, and the media.

Let's have a look at what is happening on the US markets on Thursday. Below you can find the S&P500 stocks with an unusual volume in today's session.

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.

Stay tuned for the market movements in the S&P500 index on Thursday. Check out the gap up and gap down stocks in the S&P500 index during today's session.

Tech stocks lead Wall Street higher as trade tensions ease and inflation cools. Tesla and Nvidia reach key valuation milestones.

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Stay tuned for the market movements in the S&P500 index on Tuesday. Check out the gap up and gap down stocks in the S&P500 index during today's session.

Health insurance company Humana (NYSE:HUM) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.4% year on year to $32.11 billion. The company’s full-year revenue guidance of $127 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $11.58 per share was 15% above analysts’ consensus estimates.

Curious about the S&P500 stocks that are showing activity before the opening bell on Tuesday?

The lawsuit alleges that from 2016 through at least 2021, the insurers paid hundreds of millions of dollars in illegal kickbacks to brokers.

Humana beat Q1 EPS estimates with $11.58, reaffirmed 2025 guidance, and outlined margin goals despite a drop in Medicare Advantage membership.

Wall Street traded lower on the final session of the month, heading for its third consecutive monthly loss as economic data began reflecting the impact of Trump tariffs.

Discover the top S&P500 movers in Wednesday's pre-market session and stay informed about market dynamics.

Health insurance company Humana (NYSE:HUM) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 8.4% year on year to $32.11 billion. The company’s full-year revenue guidance of $127 billion at the midpoint came in 0.7% above analysts’ estimates. Its GAAP profit of $10.30 per share was 3.4% above analysts’ consensus estimates.

According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million.

Wall Street braces for volatile Wednesday as U.S. GDP data shows unexpected economic contraction, raising fears of a recession. Pre-market futures down.

Humana’s insurance segment benefit ratio came in at 87.4% in the quarter, in line with its estimate of approximately 87.5%, reflecting medical cost trends that aligned with its expectations.

Wall Street expects the insurer to post a 10% drop in Medicare Advantage membership for 2025 but higher premiums to support an earnings beat.

Notwithstanding the resurgence seen since last week, the market is likely to end April with a monthly loss, with the S&P 500 down 0.90% with a session to go.